Ellison Lynne M, Man Yangao, Stojadinovic Alexander, Xin Hongwu, Avital Itzhak
Bon Secours Cancer Institute, Bon Secours Health System, Richmond, VA 23226, USA.
Laboratory of Oncology, the First People's Hospital of Jingzhou City, the First Hospital and Clinical Medical School of Yangtze University, Jingzhou 434008, China; Laboratory of Oncology, Center for Molecular Medicine, Medical School, Yangtze University, Jingzhou 434023, China.
Chin J Cancer Res. 2017 Feb;29(1):86-92. doi: 10.21147/j.issn.1000-9604.2017.01.10.
Although gastric cancer with peritoneal carcinomatosis is associated with poor prognosis and is generally treated with palliative systemic therapy, recent studies have shown that cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may prove to be an efficacious treatment option. In addition to reviewing the natural history of gastric cancer with peritoneal carcinomatosis, this mini-review examines literature on the efficacy of CRS and HIPEC as compared to chemotherapy and surgical options. Both randomized and non-randomized studies were summarized with the emphasis focused on overall survival. In summary, CRS and HIPEC are indeed a promising treatment option for gastric cancer with peritoneal carcinomatosis and large randomized clinical trials are warranted.
尽管伴有腹膜转移癌的胃癌预后较差，通常采用姑息性全身治疗，但最近的研究表明，细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）可能是一种有效的治疗选择。除了回顾伴有腹膜转移癌的胃癌的自然病程外，本综述还研究了与化疗和手术选择相比，CRS和HIPEC疗效的相关文献。总结了随机和非随机研究，重点关注总生存期。总之，CRS和HIPEC确实是伴有腹膜转移癌的胃癌的一种有前景的治疗选择，有必要开展大型随机临床试验。
